Ambea AB (publ)

OM:AMBEA Stock Report

Market Cap: SEK 7.9b

Ambea Valuation

Is AMBEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMBEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMBEA (SEK92.85) is trading below our estimate of fair value (SEK310.95)

Significantly Below Fair Value: AMBEA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMBEA?

Key metric: As AMBEA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AMBEA. This is calculated by dividing AMBEA's market cap by their current earnings.
What is AMBEA's PE Ratio?
PE Ratio12.9x
EarningsSEK 604.00m
Market CapSEK 7.89b

Price to Earnings Ratio vs Peers

How does AMBEA's PE Ratio compare to its peers?

The above table shows the PE ratio for AMBEA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.7x
ATT Attendo
18.8x24.3%SEK 7.5b
HUM Humana
15.3x44.7%SEK 1.9b
ARJO B Arjo
18.1x24.5%SEK 9.2b
CEVI CellaVision
34.8x22.8%SEK 5.2b
AMBEA Ambea
12.9x11.5%SEK 7.8b

Price-To-Earnings vs Peers: AMBEA is good value based on its Price-To-Earnings Ratio (12.9x) compared to the peer average (21.7x).

Price to Earnings Ratio vs Industry

How does AMBEA's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AMBEA 12.9xIndustry Avg. 18.6xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AMBEA is good value based on its Price-To-Earnings Ratio (12.9x) compared to the European Healthcare industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is AMBEA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMBEA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.9x
Fair PE Ratio21.5x

Price-To-Earnings vs Fair Ratio: AMBEA is good value based on its Price-To-Earnings Ratio (12.9x) compared to the estimated Fair Price-To-Earnings Ratio (21.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMBEA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 92.85
SEK 115.33
+24.2%
5.7%SEK 120.00SEK 106.00n/a3
Nov ’25SEK 90.05
SEK 106.00
+17.7%
5.3%SEK 110.00SEK 98.00n/a3
Oct ’25SEK 90.10
SEK 106.00
+17.6%
5.3%SEK 110.00SEK 98.00n/a3
Sep ’25SEK 91.20
SEK 106.00
+16.2%
5.3%SEK 110.00SEK 98.00n/a3
Aug ’25SEK 78.15
SEK 94.33
+20.7%
11.8%SEK 110.00SEK 85.00n/a3
Jul ’25SEK 78.60
SEK 89.33
+13.7%
12.8%SEK 105.00SEK 78.00n/a3
Jun ’25SEK 72.85
SEK 82.67
+13.5%
4.0%SEK 85.00SEK 78.00n/a3
May ’25SEK 63.45
SEK 79.67
+25.6%
4.8%SEK 85.00SEK 76.00n/a3
Apr ’25SEK 63.75
SEK 79.67
+25.0%
4.8%SEK 85.00SEK 76.00n/a3
Mar ’25SEK 61.85
SEK 78.00
+26.1%
6.5%SEK 85.00SEK 73.00n/a3
Feb ’25SEK 52.15
SEK 70.67
+35.5%
5.9%SEK 75.00SEK 65.00n/a3
Jan ’25SEK 52.60
SEK 63.33
+20.4%
13.0%SEK 75.00SEK 57.00n/a3
Dec ’24SEK 44.62
SEK 63.33
+41.9%
13.0%SEK 75.00SEK 57.00n/a3
Nov ’24SEK 40.98
SEK 57.33
+39.9%
15.7%SEK 70.00SEK 50.00SEK 90.053
Oct ’24SEK 34.58
SEK 61.75
+78.6%
17.7%SEK 75.00SEK 50.00SEK 90.104
Sep ’24SEK 38.50
SEK 61.75
+60.4%
17.7%SEK 75.00SEK 50.00SEK 91.204
Aug ’24SEK 33.96
SEK 61.25
+80.4%
18.6%SEK 75.00SEK 50.00SEK 78.154
Jul ’24SEK 35.08
SEK 62.50
+78.2%
16.5%SEK 75.00SEK 50.00SEK 78.604
Jun ’24SEK 34.12
SEK 62.50
+83.2%
16.5%SEK 75.00SEK 50.00SEK 72.854
May ’24SEK 39.00
SEK 60.88
+56.1%
19.3%SEK 75.00SEK 48.50SEK 63.454
Apr ’24SEK 36.30
SEK 60.88
+67.7%
19.3%SEK 75.00SEK 48.50SEK 63.754
Mar ’24SEK 35.48
SEK 62.13
+75.1%
20.7%SEK 75.00SEK 48.50SEK 61.854
Feb ’24SEK 39.44
SEK 66.75
+69.2%
14.1%SEK 75.00SEK 52.00SEK 52.154
Jan ’24SEK 44.02
SEK 77.00
+74.9%
10.0%SEK 90.00SEK 70.00SEK 52.604
Dec ’23SEK 51.00
SEK 77.00
+51.0%
10.0%SEK 90.00SEK 70.00SEK 44.624
Nov ’23SEK 40.48
SEK 76.50
+89.0%
10.7%SEK 90.00SEK 68.00SEK 40.984

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Arcoma

SEK 138.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.50

7D

-2.3%

1Y

42.9%

Dignitana

SEK 85.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.06

7D

-1.9%

1Y

-49.5%

Mentice

SEK 529.3m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 20.70

7D

-17.5%

1Y

-50.7%